XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, ParallelGroup Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults with Cognitive Impairment due to Depressive Disorder

Project: Research

Project Details

StatusFinished
Effective start/end date31/10/221/01/24

Keywords

  • Clinical trial
  • depression
  • Cognitive Impairment
  • Alzheimer disease